期刊
CLINICAL CANCER RESEARCH
卷 14, 期 7, 页码 1931-1937出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-07-4478
关键词
-
类别
资金
- NCI NIH HHS [R01 CA112390, T32 CA09599] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [T32CA009599, R01CA112390] Funding Source: NIH RePORTER
Encloglin (CD105) is an accessory protein of the transforming growth factor-beta receptor system expressed on vascular enclothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the context of this disease. The expression of endoglin is elevated on the enclothelial cells of healing wounds, developing embryos, inflammatory tissues, and solid tumors. Encloglin is a marker of activated endothelium, and its vascular expression is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases. Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据